menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Pfizer’s BRAFTOVI Boosts Response In Mutant Colorectal Cancer

    INDPHARMAPOST

    Tizona Therapeutics Expands Phase 1b Trial for Colorectal Cancer

    GLOBENEWSWIRE

    Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

    PR NEWSWIRE

    Biond Biologics Doses First Patient With BND-35 In Phase 1 Clinical Trial

    PR NEWSWIRE

    US FDA approves Bristol Myers` colorectal cancer therapy

    REUTERS

    GenFleet`s Fulzerasib Combo Shows Efficacy, Safety In Phase II NSCLC Trial

    PR NEWSWIRE

    ASCO 2024: Rakuten’s photoimmunotherapy & Keytruda combo shows efficacy in HNSCC

    PHARMACEUTICAL TECHNOLOGY

    Tizona Ttx-080 Phase 1b Data: Crc And Hnscc At Asco 2024

    GLOBENEWSWIRE

    KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity

    BUSINESSWIRE

    FDA Accepts sNDA for KRAZATI in Combination with Cetuximab

    BUSINESSWIRE

    Nature Medicine Study Validates Biopsy Assay in Genentech`s Ph 1b of Divarasib

    GLOBENEWSWIRE

    Lupin launches biosimilar cetuximab in pact with Enzene

    ECONOMICTIMES

    Enzene Biosciences launches Cetuximab, biosimilar of cancer drug Erbitux

    EXPRESSPHARMA

    SOLVE FSHD invests in Epic Bio for the deP of a novel treatment

    GLOBENEWSWIRE

    GenFleet receives EMA approval for phase Ib/II study of GFH925 with ERBITUX

    PR NEWSWIRE

    GenFleet & Merck Enter into Collaboration to Initiate Study Investigating GFH925

    PRNEWSWIRE

    Jacobio to Collaborate with Merck on Trial of JAB-21822 with Cetuximab

    PRNEWSWIRE

    Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822`s PII Study

    PRNEWSWIRE

    ALX starts Phase II trial of colorectal cancer combo therapy

    CLINICALTRIALSARENA

    ALX Oncology Announces First Patient Dosed in Ph2 InG Trial of Evorpacept

    GLOBENEWSWIRE

    Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

    BUSINESSWIRE

    Erasca, Lilly sign deal to assess colorectal cancer combo therapy

    CLINICALTRIALSARENA

    AVEO & Lilly Sign Trial Collaboration and Supply Agreement for ERBITUX

    GLOBENEWSWIRE

    Biond Biologics Announces First Patients Dosed with BND-22 in PI Trial

    PRNEWSWIRE

    Erasca Enters Collaboration, Supply Agreement with Eli Lilly for ERAS-007 combo

    GLOBENEWSWIRE

    Jacobio JAB-21822 + Cetuximab Completes First Dose of Colorectal Cancer Patient

    PRNEWSWIRE

    NANOBIOTIX Begins Enrollment in Global Phase III Study of NBTXR3

    BUSINESSWIRE

    Innate Pharma: Monalizumab + Cetuximab & Durvalumab Shows Anti-Tumor Activity

    BUSINESSWIRE

    Jacobio Receives IND Approval for Combo Therapy of KRAS G12C and Cetuximab Inj

    ASIAONE

    Jacobio Receives IND Approval for Comb. Therapy of KRAS G12C & Cetuximab Inj.

    PRNEWSWIRE

    Novitium`s Generic Betaine Receives Approval in the US

    FDA

    AVEO Reports Q3 2021 Financial Results and Provides Business Update

    BUSINESSWIRE

    NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly

    BUSINESSWIRE

    Tizona Begins Phase 1b Expansion Study of TTX-080 in Advanced r/r Malignancies

    BUSINESSWIRE

    FDA expands Lilly`s Erbitux label with Braftovi to treat metastatic CRC

    PHARMABIZ

    Imclone`s Biologic Cetuximab Receives Approval in the US

    FDA

    Adagrasib, Cetuximab Combo Shows Promise in Heavily Pretreated Patients

    CANCERNETWORK

    Mirati Presents +ve Data with Adagrasib in KRAS G12C-Mutated Colorectal Cancer

    PRNEWSWIRE

    Pillar Biosciences` oncoRevealTM Dx lung and colon cancer NGS

    BUSINESSWIRE

    FDA approves new dosing regimen for cetuximab

    FDA

    NICE backs Braftovi for BRAF-positive colorectal cancer

    PHARMATIMES

    Imclone’s Erbitux (Cetuximab) Receives Supplimental Approval In US

    FDA

    Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611

    PIPELINEREVIEW

    Junshi Biosciences & Merck Announce Collaboration to Explore COMBINATION

    GLOBENEWSWIRE

    Kitov Announces U.S. FDA Acceptance of INDA to Conduct Ph 1/2 Trial of NT219

    GLOBENEWSWIRE

    Innate to Present New Efficacy Data For Monalizumab in Combination Cetuximab

    GLOBENEWSWIRE

    Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) in combo

    BUSINESSWIRE

    US FDA grants priority review status to Pfizer`s sNDA for Braftov

    PHARMABIZ

    U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI

    BUSINESS WIRE

    EMA validated Pierre Fabre’s application for a Braftov and Mektovi combination

    PHARMATIMES

    Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA®

    BIOSPACE

    Merck gets Chinese approval for Erbitux with Folfox or Folfiri colorectal cancer

    PHARMABIZ

    Innate Pharma and AstraZeneca take monalizumab into phase 3

    PMLIVE

    Pierre Fabre to Present New Data at the ESMO Annual Congress

    BUSINESSWIRE

    Roche, Merck, Novartis and others hike prices on 83 meds starting in July

    FIERCE PHARMA

    Pierre Fabre`s triplet therapy makes strong showing in colorectal cancer

    PHARMAFILE

    Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer

    BIOSPACE

    Pierre Fabre and its partner Array BioPharma announce interim analysis results

    BUSINESSWIRE

    Another effort on pancreatic cancer flops, as Boston Biomedical cans Ph 3 test

    FIERCE BIOTECH

    Array played with Pfizer’s eagerness to land a deal on time

    FIERCE PHARMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.